$45.54
0.98%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US74006W1080
Symbol
PRAX

Praxis Precision Medicines Inc Target price 2025 - Analyst rating & recommendation

Praxis Precision Medicines Inc Classifications & Recommendation:

Buy
89%
Hold
6%
Sell
6%

Praxis Precision Medicines Inc Price Target

Target Price $84.15
Price $45.54
Potential
Number of Estimates 14
14 Analysts have issued a price target Praxis Precision Medicines Inc 2026 . The average Praxis Precision Medicines Inc target price is $84.15. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 16 Analysts recommend Praxis Precision Medicines Inc to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Praxis Precision Medicines Inc stock has an average upside potential 2026 of . Most analysts recommend the Praxis Precision Medicines Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 8.55 0.11
248.98% 98.69%
EBITDA Margin -2,336.96% -266,587.27%
54.54% 11,307.44%
Net Margin -2,138.25% -255,157.82%
57.51% 11,833.05%

14 Analysts have issued a sales forecast Praxis Precision Medicines Inc 2025 . The average Praxis Precision Medicines Inc sales estimate is

$112k
Unlock
. This is
98.56% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.2m 85.14%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $8.6m 248.98%
2025
$112k 98.69%
Unlock
2026
$140k 25.04%
Unlock
2027
$66.9m 47,583.54%
Unlock
2028
$158m 136.71%
Unlock
2029
$442m 179.10%
Unlock
2030
$873m 97.43%
Unlock
2031
$1.3b 47.14%
Unlock
2032
$1.7b 33.64%
Unlock

4 Analysts have issued an Praxis Precision Medicines Inc EBITDA forecast 2025. The average Praxis Precision Medicines Inc EBITDA estimate is

$-299m
Unlock
. This is
10.23% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-298m 9.82%
Unlock
, the lowest is
$-297m 9.32%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-200m 58.65%
2025
$-299m 49.70%
Unlock
2026
$-273m 8.67%
Unlock
2027
$-279m 2.09%
Unlock
2028
$-266m 4.53%
Unlock
2029
$-204m 23.21%
Unlock
2030
$-145m 29.12%
Unlock
2031
$-51.0m 64.77%
Unlock
2032
$40.1m 178.60%
Unlock

EBITDA Margin

2024 -2,336.96% 54.54%
2025
-266,587.27% 11,307.44%
Unlock
2026
-194,774.55% 26.94%
Unlock
2027
-416.86% 99.79%
Unlock
2028
-168.12% 59.67%
Unlock
2029
-46.26% 72.48%
Unlock
2030
-16.61% 64.09%
Unlock
2031
-3.98% 76.04%
Unlock
2032
2.34% 158.79%
Unlock

14 Praxis Precision Medicines Inc Analysts have issued a net profit forecast 2025. The average Praxis Precision Medicines Inc net profit estimate is

$-286m
Unlock
. This is
14.06% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-275m 9.75%
Unlock
, the lowest is
$-302m 20.18%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-183m 48.30%
2025
$-286m 56.60%
Unlock
2026
$-261m 8.73%
Unlock
2027
$-222m 15.04%
Unlock
2028
$-149m 32.74%
Unlock
2029
$37.2m 124.92%
Unlock
2030
$350m 840.34%
Unlock
2031
$545m 55.78%
Unlock
2032
$726m 33.12%
Unlock

Net Margin

2024 -2,138.25% 57.51%
2025
-255,157.82% 11,833.05%
Unlock
2026
-186,306.68% 26.98%
Unlock
2027
-331.82% 99.82%
Unlock
2028
-94.29% 71.58%
Unlock
2029
8.42% 108.93%
Unlock
2030
40.10% 376.25%
Unlock
2031
42.45% 5.86%
Unlock
2032
42.28% 0.40%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -10.21 -13.61
45.37% 33.30%
P/E negative
EV/Sales 5,856.86

14 Analysts have issued a Praxis Precision Medicines Inc forecast for earnings per share. The average Praxis Precision Medicines Inc EPS is

$-13.61
Unlock
. This is
16.52% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-13.09 12.07%
Unlock
, the lowest is
$-14.34 22.77%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-10.21 45.37%
2025
$-13.61 33.30%
Unlock
2026
$-12.42 8.74%
Unlock
2027
$-10.55 15.06%
Unlock
2028
$-7.10 32.70%
Unlock
2029
$1.77 124.93%
Unlock
2030
$16.63 839.55%
Unlock
2031
$25.91 55.80%
Unlock
2032
$34.49 33.11%
Unlock

P/E ratio

Current -3.90 49.12%
2025
-3.35 14.08%
Unlock
2026
-3.67 9.55%
Unlock
2027
-4.32 17.71%
Unlock
2028
-6.42 48.61%
Unlock
2029
25.75 501.09%
Unlock
2030
2.74 89.36%
Unlock
2031
1.76 35.77%
Unlock
2032
1.32 25.00%
Unlock

Based on analysts' sales estimates for 2025, the Praxis Precision Medicines Inc stock is valued at an EV/Sales of

5,856.86
Unlock
and an P/S ratio of
8,542.07
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 84.57 72.39%
2025
5,856.86 6,825.46%
Unlock
2026
4,685.49 20.00%
Unlock
2027
9.82 99.79%
Unlock
2028
4.15 57.75%
Unlock
2029
1.49 64.17%
Unlock
2030
0.75 49.35%
Unlock
2031
0.51 32.04%
Unlock
2032
0.38 25.19%
Unlock

P/S ratio

Current 123.35 75.58%
2025
8,542.07 6,825.10%
Unlock
2026
6,833.65 20.00%
Unlock
2027
14.33 99.79%
Unlock
2028
6.05 57.75%
Unlock
2029
2.17 64.17%
Unlock
2030
1.10 49.35%
Unlock
2031
0.75 32.04%
Unlock
2032
0.56 25.17%
Unlock

Current Praxis Precision Medicines Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 05 2025
Chardan Capital
Locked
Locked
Locked Jul 29 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 18 2025
Oppenheimer
Locked
Locked
Locked Jul 08 2025
Needham
Locked
Locked
Locked Jun 12 2025
Chardan Capital
Locked
Locked
Locked May 07 2025
Needham
Locked
Locked
Locked May 05 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 05 2025
Locked
Chardan Capital:
Locked
Locked
Jul 29 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 18 2025
Locked
Oppenheimer:
Locked
Locked
Jul 08 2025
Locked
Needham:
Locked
Locked
Jun 12 2025
Locked
Chardan Capital:
Locked
Locked
May 07 2025
Locked
Needham:
Locked
Locked
May 05 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today